Efficacy of aflibercept for Macular edema secondary to central retinal vein occlusion (CRVO)

Efficacy of aflibercept for Macular edema secondary to central retinal vein occlusion (CRVO) - Investigation of Eylea for CRVO

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014505

Enrollment

Registered

2014-07-08

Start date

2014-07-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

central retinal vein occlusion

Interventions

Eylea (aflibercept)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with ME due to CRVO 2)Retinal thickness 300um and over 3)BCVA in the study eye between 0.1 to 1.0(Decimal VA) 4)Adults 20 years and older 5)Willomgness to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1) The following exclusions apply to the study eye only. Prior treatment with steroids (<3 months) History of vitrectomy surgery, submacular surgery, or other surgical intervention. 2) Active intraocular inflammation. 3) Hypersensitivity or allergy to fluorescein or indocyanine green, clinically significant drug allergy or known hypersensitivity to therapeutic or diagnostic protein products, or to any of the study drugs or their components. 4) pregnant women and nursing mothers. 5) Patient who the doctor in charge judges are ineligible for the study.

Design outcomes

Primary

Measure	Time frame
VA change from baseline to month 12 Change of retinal thickness, chroidal thickness and edema from baseline to month 12	—

Countries

Japan

Contacts

Public ContactKenji Sogawa

Asahikawa Medical University Department of Ophthalmology

cdh72740@yahoo.co.jp0166-65-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026